|  Z79 |  | Long term (current) drug therapy   | 
	
		|  |  | 
	
		| Includes | long term (current) drug use for prophylactic purposes 
 |  
		| CodeAlso | any therapeutic drug level monitoring (Z51.81) 
 |  
		| Excludes2 | drug abuse and dependence (F11-F19) drug use complicating pregnancy, childbirth, and the puerperium (O99.32-)
 
 |  | 
|  |  | 
	
		|  Z79.0 |  | Long term (current) use of anticoagulants and antithrombotics/antiplatelets |  
		|  |  | 
	
		| Excludes2 | long term (current) use of aspirin (Z79.82) 
 |  |  |  |  | 
	
		|  Z79.01 |  | Long term (current) use of anticoagulants |  |  |  |  | 
	
		|  Z79.02 |  | Long term (current) use of antithrombotics/antiplatelets |  
		|  |  |  |  |  | 
|  |  | 
	
		|  Z79.1 |  | Long term (current) use of non-steroidal anti-inflammatories (NSAID) |  
		|  |  | 
	
		| Excludes2 | long term (current) use of aspirin (Z79.82) 
 |  
		| nonPrimary | Yes 
 |  |  | 
|  |  | 
	
		|  Z79.2 |  | Long term (current) use of antibiotics |  
		|  |  |  |  | 
|  |  | 
	
		|  Z79.3 |  | Long term (current) use of hormonal contraceptives |  
		|  |  | 
| Long term (current) use of birth control pill or patch |  |  | 
|  |  | 
	
		|  Z79.4 |  | Long term (current) use of insulin |  
		|  |  | 
	
		| Excludes2 | long-term (current) use of injectable non-insulin antidiabetic drugs (Z79.85) long term (current) use of oral antidiabetic drugs (Z79.84)
 long term (current) use of oral hypoglycemic drugs (Z79.84)
 
 |  |  | 
|  |  | 
	
		|  Z79.5 |  | Long term (current) use of steroids |  |  |  | 
	
		|  Z79.51 |  | Long term (current) use of inhaled steroids |  
		|  |  |  |  |  |  |  | 
	
		|  Z79.52 |  | Long term (current) use of systemic steroids |  
		|  |  |  |  |  | 
|  |  | 
	
		|  Z79.6 |  | Long term (current) use of immunomodulators and immunosuppressants |  
		|  |  | 
	
		| Excludes2 | long term (current) use of steroids (Z79.5-) long term (current) use of agents affecting estrogen receptors and estrogen levels (Z79.81-)
 
 |  |  |  |  | 
	
		|  Z79.60 |  | Long term (current) use of unspecified immunomodulators and immunosuppressants |  |  |  |  | 
	
		|  Z79.61 |  | Long term (current) use of immunomodulator |  
		|  |  | 
| Long term (current) use of apremilast |  | Long term (current) use of immunomodulatory imide drug |  | Long term (current) use of lenalidomide |  | Long term (current) use of pomalidomide |  |  |  |  |  | 
	
		|  Z79.62 |  | Long term (current) use of immunosuppressant |  |  |  | 
	
		|  Z79.620 |  | Long term (current) use of immunosuppressive biologic |  
		|  |  | 
| Long term (current) use of adalimumab |  | Long term (current) use of etanercept |  | Long term (current) use of infliximab |  | Long term (current) use of monoclonal antibodies |  |  |  |  |  | 
	
		|  Z79.621 |  | Long term (current) use of calcineurin inhibitor |  
		|  |  | 
| Long term (current) use of cyclosporine |  | Long term (current) use of tacrolimus |  |  |  |  |  | 
	
		|  Z79.622 |  | Long term (current) use of Janus kinase inhibitor |  
		|  |  | 
| Long term (current) use of tofacitinib |  |  |  |  |  | 
	
		|  Z79.623 |  | Long term (current) use of mammalian target of rapamycin (mTOR) inhibitor |  
		|  |  | 
| Long term (current) use of sirolimus |  |  |  |  |  | 
	
		|  Z79.624 |  | Long term (current) use of inhibitors of nucleotide synthesis |  
		|  |  | 
| Long term (current) use of azathioprine |  | Long term (current) use of mycophenolate |  | Long term (current) use of purine synthesis (IMDH) inhibitors |  |  |  |  |  |  | 
	
		|  Z79.63 |  | Long term (current) use of chemotherapeutic agent |  |  |  | 
	
		|  Z79.630 |  | Long term (current) use of alkylating agent |  
		|  |  | 
| Long term (current) use of chlorambucil |  | Long term (current) use of cisplatin |  | Long term (current) use of cyclophosphamide |  |  |  |  |  | 
	
		|  Z79.631 |  | Long term (current) use of antimetabolite agent |  
		|  |  | 
| Long term (current) use of 5-fluorouracil |  | Long term (current) use of 6-mercaptopurine |  | Long term (current) use of cytarabine |  | Long term (current) use of methotrexate |  |  |  |  |  | 
	
		|  Z79.632 |  | Long term (current) use of antitumor antibiotic |  
		|  |  | 
| Long term (current) use of bleomycin |  | Long term (current) use of doxorubicin |  | Long term (current) use of mitomycin C |  |  |  |  |  | 
	
		|  Z79.633 |  | Long term (current) use of mitotic inhibitor |  
		|  |  | 
| Long term (current) use of paclitaxel |  | Long term (current) use of plant alkaloids |  | Long term (current) use of vinblastine |  | Long term (current) use of vincristine |  |  |  |  |  | 
	
		|  Z79.634 |  | Long term (current) use of topoisomerase inhibitor |  
		|  |  | 
| Long term (current) use of etoposide |  | Long term (current) use of irinotecan |  | Long term (current) use of topotecan |  |  |  |  |  |  | 
	
		|  Z79.64 |  | Long term (current) use of myelosuppressive agent |  
		|  |  | 
| Long term (current) use of hydroxyurea |  |  |  |  |  | 
	
		|  Z79.69 |  | Long term (current) use of other immunomodulators and immunosuppressants |  |  | 
|  |  | 
	
		|  Z79.8 |  | Other long term (current) drug therapy |  |  |  | 
	
		|  Z79.81 |  | Long term (current) use of agents affecting estrogen receptors and estrogen levels |  
		|  |  | 
	
		| CodeFirst | , if applicable: malignant neoplasm of breast (C50.-)
 malignant neoplasm of prostate (C61)
 
 |  
		| UseAdditionalCode | code, if applicable, to identify: estrogen receptor positive status (Z17.0)
 family history of breast cancer (Z80.3)
 genetic susceptibility to malignant neoplasm (cancer) (Z15.0-)
 personal history of breast cancer (Z85.3)
 personal history of prostate cancer (Z85.46)
 postmenopausal status (Z78.0)
 
 |  
		| Excludes1 | hormone replacement therapy (Z79.890) 
 |  |  |  |  | 
	
		|  Z79.810 |  | Long term (current) use of selective estrogen receptor modulators (SERMs) |  
		|  |  | 
| Long term (current) use of raloxifene (Evista) |  | Long term (current) use of tamoxifen (Nolvadex) |  | Long term (current) use of toremifene (Fareston) |  
		| nonPrimary | Yes 
 |  |  |  |  |  | 
	
		|  Z79.811 |  | Long term (current) use of aromatase inhibitors |  
		|  |  | 
| Long term (current) use of anastrozole (Arimidex) |  | Long term (current) use of exemestane (Aromasin) |  | Long term (current) use of letrozole (Femara) |  
		| nonPrimary | Yes 
 |  |  |  |  |  | 
	
		|  Z79.818 |  | Long term (current) use of other agents affecting estrogen receptors and estrogen levels |  
		|  |  | 
| Long term (current) use of estrogen receptor downregulators |  | Long term (current) use of fulvestrant (Faslodex) |  | Long term (current) use of gonadotropin-releasing hormone (GnRH) agonist |  | Long term (current) use of goserelin acetate (Zoladex) |  | Long term (current) use of leuprolide acetate (leuprorelin) (Lupron) |  | Long term (current) use of megestrol acetate (Megace) |  
		| nonPrimary | Yes 
 |  |  |  |  |  |  | 
	
		|  Z79.82 |  | Long term (current) use of aspirin |  |  |  |  | 
	
		|  Z79.83 |  | Long term (current) use of bisphosphonates |  
		|  |  |  |  |  |  |  | 
	
		|  Z79.84 |  | Long term (current) use of oral hypoglycemic drugs |  
		|  |  | 
| Long term (current) use of oral antidiabetic drugs |  
		| Excludes2 | long-term (current) use of injectable non-insulin antidiabetic drugs (Z79.85) long term (current) use of insulin (Z79.4)
 
 |  
		| nonPrimary | Yes 
 |  |  |  |  |  | 
	
		|  Z79.85 |  | Long-term (current) use of injectable non-insulin antidiabetic drugs |  
		|  |  | 
	
		| Excludes2 | long term (current) use of insulin (Z79.4) long term (current) use of oral hypoglycemic drugs (Z79.84)
 
 |  |  |  |  |  | 
	
		|  Z79.89 |  | Other long term (current) drug therapy |  |  |  | 
	
		|  Z79.890 |  | Hormone replacement therapy |  
		|  |  |  |  |  |  |  | 
	
		|  Z79.891 |  | Long term (current) use of opiate analgesic |  
		|  |  | 
| Long term (current) use of methadone for pain management |  
		| Excludes1 | methodone use NOS (F11.9-) use of methodone for treatment of heroin addiction (F11.2-)
 
 |  |  |  |  |  | 
	
		|  Z79.899 |  | Other long term (current) drug therapy |  |  |  |